Description

Rusfertide is an investigational peptide therapeutic designed to mimic natural hepcidin’s function. It binds to and degrades ferroportin, the cellular iron exporter, resulting in reduced serum iron and controlled erythropoiesis. This mechanism allows effective regulation of red blood cell production and hematocrit, which is particularly valuable for laboratory studies of polycythemia vera (PV), ?-thalassemia, and hereditary hemochromatosis. Rusfertide has demonstrated promising results in phase III studies, significantly reducing the need for therapeutic phlebotomy and improving hematocrit control in PV models while demonstrating a favorable safety profile.

Manufactured in a GMP-certified facility and offered with a high purity of 99.83%, this product is optimized for dependable and reproducible research applications.

Product Specifications

Mechanism of Action & Research Applications

Rusfertide emulates hepcidin’s regulatory function by binding to ferroportin, leading to its degradation and subsequent reduction in cellular iron export. This leads to lower serum iron, controlled hematocrit, and alleviated erythrocytosis. In clinical models of polycythemia vera, Rusfertide significantly reduced phlebotomy dependence and improved hematocrit control, offering a potential breakthrough for iron metabolism-based erythrocytosis research.

Applications include:

• Polycythemia vera model studies

• Iron overload and ?-thalassemia research

• Iron homeostasis and erythropoiesis investigation

Side Effects (Research Context Only)

In experimental models, Rusfertide may reduce hematocrit, lower serum iron, and reduce phlebotomy dependency without triggering significant adverse events. Observations from Phase III studies report mostly mild, self-limited reactions and consistent hematocrit control outcomes.

Disclaimer

Rusfertide Acetate is strictly for laboratory research use only. It is not approved for clinical, therapeutic, or diagnostic use in humans or animals.